ArticleFrontiers in physiology2026
Incremental value of placental miR-7641 and ferroptosis-related phenotypes in risk stratification of severe preeclampsia.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the incremental value of placental miR-7641 and ferroptosis-related molecular phenotypes beyond mean arterial pressure (MAP) for risk stratification of severe preeclampsia (SPE). Methods: This retrospective study enrolled 64 women with SPE and 70 normotensive controls who underwent cesarean delivery between January 2023 and October 2024. Placental miR-7641 was quantified by qRT-PCR, and MDA, COX2, and GPX4 were measured by ELISA/TBA assay. Independent predictors were identified through multivariable logistic regression, and nested models were constructed (Model 1: MAP alone; Model 2: MAP plus independently significant molecular markers). Incremental discrimination was assessed using the net reclassification improvement (NRI), integrated discrimination improvement (IDI), and DeLong test. The SPE group was further stratified by gestational age at delivery into early-onset PE (EOPE; <34 weeks, n = 21) and late-onset PE (LOPE; ≥34 weeks, n = 43) for exploratory subgroup analysis. Results: Compared with controls, SPE placentas exhibited significantly elevated miR-7641, MDA, and COX2 levels alongside significantly reduced GPX4 (all P < 0.001), with more pronounced alterations in the EOPE subgroup (all Cohen's d > 0.8). In multivariable analysis, MAP (OR = 1.12), miR-7641 (OR = 2.24), and MDA (OR = 1.45) were independently associated with SPE. Model 2 improved the AUC from 0.843 to 0.906 compared with Model 1 (P = 0.008), with an NRI of 0.573 (P < 0.001) and an IDI of 0.112 (P < 0.001). Sensitivity analyses demonstrated that the associations attenuated but persisted after adjustment for gestational age, supporting the robustness of the findings. Conclusions: Placental miR-7641 and MDA provide incremental risk stratification information beyond MAP, with ferroptosis-related molecular phenotypes being more prominent in EOPE. These findings constitute proof of concept; clinical translation awaits external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.